PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28835573-10 2017 Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Tegafur 54-68 thymidylate synthetase Homo sapiens 150-152 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 thymidylate synthetase Homo sapiens 230-250 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 thymidylate synthetase Homo sapiens 252-254 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 257-264 thymidylate synthetase Homo sapiens 84-104 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 12-26 thymidylate synthetase Homo sapiens 70-90 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 12-26 thymidylate synthetase Homo sapiens 92-94 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 28-31 thymidylate synthetase Homo sapiens 70-90 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 28-31 thymidylate synthetase Homo sapiens 92-94 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 266-269 thymidylate synthetase Homo sapiens 84-104 17143493-1 2007 The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues. Tegafur 90-97 thymidylate synthetase Homo sapiens 165-185 17695427-0 2007 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Tegafur 160-163 thymidylate synthetase Homo sapiens 20-40 17143493-6 2007 The TS activity was decreased by NAC with UFT, and the addition of CPA resulted in an increased inhibition of TS activity. Tegafur 42-45 thymidylate synthetase Homo sapiens 4-6 22870097-0 2010 Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Tegafur 68-82 thymidylate synthetase Homo sapiens 156-176 17143493-1 2007 The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues. Tegafur 99-102 thymidylate synthetase Homo sapiens 165-185 14636615-0 2003 Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Tegafur 101-115 thymidylate synthetase Homo sapiens 40-60 15785747-6 2005 In patients with stage II-III NSCLCs, furthermore, the survival of UFT (a combination of tegafur and uracil)-treated patients with TS-negative tumours was significantly better than those of any other patients. Tegafur 89-96 thymidylate synthetase Homo sapiens 131-133 15218314-0 2004 Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Tegafur 151-158 thymidylate synthetase Homo sapiens 4-24 15218314-1 2004 OBJECTIVE: To assess the thymidylate synthase protein (TS) in tumor cells of resected gastric cancer patients treated with adjuvant tegafur (TG), we reviewed the outcome of 94 randomized patients treated either with adjuvant TG plus mitomycin C (MMC) or MMC alone. Tegafur 132-139 thymidylate synthetase Homo sapiens 25-45 15218314-1 2004 OBJECTIVE: To assess the thymidylate synthase protein (TS) in tumor cells of resected gastric cancer patients treated with adjuvant tegafur (TG), we reviewed the outcome of 94 randomized patients treated either with adjuvant TG plus mitomycin C (MMC) or MMC alone. Tegafur 141-143 thymidylate synthetase Homo sapiens 25-45 14636615-0 2003 Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Tegafur 117-120 thymidylate synthetase Homo sapiens 40-60 14636615-2 2003 We investigated the relationship between the level of tumoural TS expression and response to tegafur/uracil (UFT) in 26 patients with oral squamous cell carcinoma. Tegafur 93-100 thymidylate synthetase Homo sapiens 63-65 14636615-2 2003 We investigated the relationship between the level of tumoural TS expression and response to tegafur/uracil (UFT) in 26 patients with oral squamous cell carcinoma. Tegafur 109-112 thymidylate synthetase Homo sapiens 63-65 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 166-173 thymidylate synthetase Homo sapiens 0-20 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 166-173 thymidylate synthetase Homo sapiens 22-24 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 175-178 thymidylate synthetase Homo sapiens 0-20 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 175-178 thymidylate synthetase Homo sapiens 22-24 7487125-0 1995 [UFT/CDDP preoperative chemotherapy for progressive gastric cancer--histological antitumor effects and thymidylate synthase inhibition rate]. Tegafur 1-4 thymidylate synthetase Homo sapiens 103-123 11201382-4 2001 TS-1, which contains tegafur and dihydroxypyridine (CDHP), a potent DPD inhibitor, is a promising anticancer drug. Tegafur 21-28 thymidylate synthetase Homo sapiens 0-2 10769701-13 2000 CONCLUSION: Based on our results for TSIR, Tegafur-uracil may induce apoptosis of tumor cells in patients by the inhibition of thymidylate synthase. Tegafur 43-57 thymidylate synthetase Homo sapiens 127-147 9239165-0 1997 [Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat]. Tegafur 48-51 thymidylate synthetase Homo sapiens 140-160 8765432-0 1996 Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Tegafur 65-79 thymidylate synthetase Homo sapiens 0-20 8765432-0 1996 Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Tegafur 81-84 thymidylate synthetase Homo sapiens 0-20 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 134-137 thymidylate synthetase Homo sapiens 59-79 8468974-0 1993 Dependence of the thymidylate synthase inhibition rate on the interval after the last administration of tegafur in sigmoid colon cancer patients. Tegafur 104-111 thymidylate synthetase Homo sapiens 18-38 8464418-0 1993 [Changes of the number of FdUMP binding sites of thymidylate synthase and folate pools in human colorectal carcinomas following the administration of tegafur and uracil: preliminary report]. Tegafur 150-157 thymidylate synthetase Homo sapiens 49-69 1992915-0 1991 [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT]. Tegafur 117-124 thymidylate synthetase Homo sapiens 56-76 1519926-0 1992 [Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tegafur 32-39 thymidylate synthetase Homo sapiens 148-168 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 134-137 thymidylate synthetase Homo sapiens 81-83 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 170-206 thymidylate synthetase Homo sapiens 59-79 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 170-206 thymidylate synthetase Homo sapiens 81-83 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 208-215 thymidylate synthetase Homo sapiens 59-79 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 208-215 thymidylate synthetase Homo sapiens 81-83 6426401-4 1984 Thymidylate synthase was inhibited more severely by oral administration of UFT (30 mg/kg). Tegafur 75-78 thymidylate synthetase Homo sapiens 0-20 32838518-6 2020 Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Tegafur 132-139 thymidylate synthetase Homo sapiens 66-86